Spots Global Cancer Trial Database for Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
Official Title: Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
Study ID: NCT01272557
Conditions
Study Description
Brief Summary: This study is a prospective, randomized, open-label, multicenter phase IIB trial in order to determine time to progression of the combination therapy sorafenib plus doxorubicin against standard-of-care sorafenib in advanced HCC not amenable to non-systemic treatment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität, Düsseldorf, , Germany
Martin-Luther-University Halle-Wittenberg, Halle (Saale), , Germany
Universitätsklinikum des Saarlande, Homburg/Saar, , Germany
Ortenau Klinikum Lahr-Ettenheim, Lahr, , Germany
Universitätsklinikum Leipzig, Leipzig, , Germany
Klinikum Ludwigsburg, Ludwigsburg, , Germany
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
